Abstract:Cellular senescence is implicated in ageing and associated with a broad spectrum of age-related diseases. Importantly, a cell can initiate the senescence program irrespective of the organism's age. Various stress signals, including those defined as ageing hallmarks and alterations leading to cancer development, oncogene activation, or loss of cancer-suppressive functions, can trigger cellular senescence. The primary outcome of these alterations is the activation of nuclear factor (NF)-κB, thereby inducing the senescence-associated secretory phenotype (SASP). Proinflammatory cytokines and chemokines, components of this phenotype, contribute to chronic systemic sterile inflammation, commonly referred to as inflamm-ageing. This inflammation is linked to age-related diseases (ARDs), frailty, and increased mortality in older individuals. Additionally, senescent cells (SCs) accumulate in multiple tissues with age and are believed to underlie the organism functional decline, as demonstrated by models. An escalating effort has been dedicated to identify senotherapeutics that selectively target SCs by inducing apoptosis; these drugs are termed senolytics. Concurrently, small molecules that suppress senescent phenotypes without causing cell death are known as senomorphics. Both natural and synthetic senotherapeutics, along with immunotherapies employing immune cell-mediated clearance of SCs, currently represent the most promising strategies to combat ageing and ARDs. Indeed, it is fascinating to observe that information regarding the immune reaction to SCs indicates that regulation by specific lymphocyte subsets, elevated in the oldest centenarians, plays a role in attaining extreme longevity. Regardless, the application of methods already utilized in cancer treatment, such as CAR cells and monoclonal antibodies, broadens the spectrum of potential approaches to be utilized.

Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

Senolytics improve physical function and increase lifespan in old age

Targeting Senescent Cells for a Healthier Longevity: the Roadmap for an Era of Global Aging

Senescent Cell Depletion Through Targeting BCL-Family Proteins and Mitochondria

Senescence as a therapeutic target in cancer and age-related diseases

Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis

Targeting senescent cells alleviates obesity-induced metabolic dysfunction

Senotherapeutics to Counteract Senescent Cells Are Prominent Topics in the Context of Anti-Ageing Strategies

Repurposing the plant-derived compound apigenin for senomorphic effect in antiaging pipelines

Targeting cellular senescence with senotherapeutics: senolytics and senomorphics

Aging, Senescent Cells, and Senolytic Drugs: The Path to Translation

Impaired immune surveillance accelerates accumulation of senescent cells and aging

Targeting Senescent Cells and Tumor Therapy (Review)

Targeting cellular senescence in metabolic disease

Why Senescent Cells Are Resistant to Apoptosis: An Insight for Senolytic Development

Suppressed basal mitophagy drives cellular aging phenotypes that can be reversed by a p62-targeting small molecule

Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice

Senescent Cells: Emerging Targets for Human Aging and Age-Related Diseases

Emerging Therapeutic Approaches to Target the Dark Side of Senescent Cells: New Hopes to Treat Aging as a Disease and to Delay Age-Related Pathologies